2025-04-28 14:25Financial Performance - The company's operating revenue for Q1 2025 was RMB 287.34 million, a decrease of 11.54% compared to RMB 324.81 million in the same period last year[4]. - Net profit attributable to shareholders was RMB 41.12 million, a significant increase of 115.11% from a loss of RMB 272.22 million in the previous year[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 25.66 million, up 109.14% from a loss of RMB 280.67 million in the same period last year[4]. - Basic and diluted earnings per share were both RMB 0.05, reflecting an increase of 113.89% from a loss of RMB 0.36 per share in the same period last year[4]. - Operating profit for Q1 2025 was CNY 49,382,588.17, a significant recovery from a loss of CNY 293,008,274.73 in Q1 2024[23]. - Net profit for Q1 2025 reached CNY 41,119,465.25, compared to a net loss of CNY 273,363,603.07 in Q1 2024, marking a turnaround[23]. Cash Flow and Assets - The net cash flow from operating activities decreased by 45.69%, amounting to RMB 65.15 million compared to RMB 119.95 million in the previous year[4]. - Cash flow from operating activities in Q1 2025 was CNY 65,149,201.16, down from CNY 119,953,519.31 in Q1 2024[27]. - Cash inflow from investment activities in Q1 2025 was CNY 617,613,712.48, a substantial increase from CNY 111,453,520.72 in Q1 2024[27]. - Cash outflow from investment activities in Q1 2025 was CNY 951,573,490.95, compared to CNY 179,015,819.37 in Q1 2024, indicating increased investment[27]. - Cash and cash equivalents decreased from RMB 965.2 million to RMB 676.6 million, a decline of approximately 29.9%[17]. - The ending balance of cash and cash equivalents was $676,571,156.45, down from $2,865,314,156.35 at the beginning of the period[28]. Assets and Liabilities - Total assets at the end of the reporting period were RMB 9.42 billion, a slight increase of 0.30% from RMB 9.40 billion at the end of the previous year[5]. - Total assets amounted to CNY 9,424,658,609.52, slightly up from CNY 9,396,152,610.45 in the previous period[20]. - Total current assets increased slightly from RMB 5.03 billion to RMB 5.06 billion, an increase of about 0.6%[18]. - Total current liabilities decreased from RMB 1.11 billion to RMB 1.10 billion, a reduction of about 0.8%[19]. - Non-current liabilities increased from RMB 206.4 million to RMB 217.8 million, an increase of approximately 5.7%[19]. - Total liabilities were CNY 1,315,452,686.46, showing a minor decrease from CNY 1,316,964,356.49[20]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 48,730[13]. - The company has a significant shareholder, Feng Yuxia, holding 22.30% of shares[13]. - The company has not reported any changes in the participation of major shareholders in margin trading or securities lending[14]. Market Activity - The new signed orders amount to approximately RMB 430 million during the reporting period, with a total backlog of RMB 2.2 billion[15]. - The company is focused on expanding its market presence and enhancing its product offerings[15]. Non-Recurring Items - Non-recurring gains and losses amounted to RMB 15.46 million, with government subsidies contributing RMB 4.93 million[9]. - The net profit from laboratory services was a loss of RMB 41.34 million, a decline of 96.47% year-on-year, primarily due to intensified industry competition[5]. - The company reported a net gain of RMB 50.38 million from changes in the fair value of biological assets during the reporting period[5]. Return on Assets - The weighted average return on net assets increased by 3.86 percentage points to 0.51% compared to -3.35% in the previous year[4].